ATE510556T1 - Verwendung von erythropoietin - Google Patents
Verwendung von erythropoietinInfo
- Publication number
- ATE510556T1 ATE510556T1 AT03790911T AT03790911T ATE510556T1 AT E510556 T1 ATE510556 T1 AT E510556T1 AT 03790911 T AT03790911 T AT 03790911T AT 03790911 T AT03790911 T AT 03790911T AT E510556 T1 ATE510556 T1 AT E510556T1
- Authority
- AT
- Austria
- Prior art keywords
- erythropoietin
- Prior art date
Links
- 102000003951 Erythropoietin Human genes 0.000 title 1
- 108090000394 Erythropoietin Proteins 0.000 title 1
- 229940105423 erythropoietin Drugs 0.000 title 1
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Toxicology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP02019100 | 2002-08-29 | ||
| PCT/EP2003/009194 WO2004019972A1 (en) | 2002-08-29 | 2003-08-20 | Use of erythopoietin |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE510556T1 true ATE510556T1 (de) | 2011-06-15 |
Family
ID=31970265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03790911T ATE510556T1 (de) | 2002-08-29 | 2003-08-20 | Verwendung von erythropoietin |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US7459435B2 (de) |
| EP (1) | EP1536823B1 (de) |
| JP (1) | JP5128048B2 (de) |
| KR (1) | KR20050057054A (de) |
| CN (1) | CN1311866C (de) |
| AR (1) | AR041061A1 (de) |
| AT (1) | ATE510556T1 (de) |
| AU (1) | AU2003251713B2 (de) |
| BR (1) | BRPI0313792B8 (de) |
| CA (1) | CA2496581C (de) |
| ES (1) | ES2364651T3 (de) |
| MX (1) | MXPA05002067A (de) |
| PL (1) | PL209699B1 (de) |
| RU (1) | RU2305554C2 (de) |
| WO (1) | WO2004019972A1 (de) |
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL1696947T3 (pl) | 2003-12-19 | 2014-08-29 | Hoffmann La Roche | Zastosowanie erytropoetyny w leczeniu zaburzeń dystrybucji żelaza w przewlekłych chorobach zapalnych jelit |
| JP2008505119A (ja) * | 2004-06-30 | 2008-02-21 | ネクター セラピューティクス アラバマ，コーポレイション | 高分子−第ｉｘ因子部分の抱合体 |
| WO2006061853A2 (en) * | 2004-12-10 | 2006-06-15 | Serum Institute Of India Limited | Novel erythropoietic compounds and a process for producing erythropoietic compounds |
| US8048849B2 (en) | 2006-02-03 | 2011-11-01 | Modigene, Inc. | Long-acting polypeptides and methods of producing same |
| US8450269B2 (en) | 2006-02-03 | 2013-05-28 | Prolor Biotech Ltd. | Long-acting growth hormone and methods of producing same |
| US20150038413A1 (en) | 2006-02-03 | 2015-02-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US8048848B2 (en) | 2006-02-03 | 2011-11-01 | Prolor Biotech Ltd. | Long-acting interferons and derivatives thereof and methods thereof |
| US20140113860A1 (en) | 2006-02-03 | 2014-04-24 | Prolor Biotech Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10351615B2 (en) | 2006-02-03 | 2019-07-16 | Opko Biologics Ltd. | Methods of treatment with long-acting growth hormone |
| US8304386B2 (en) * | 2006-02-03 | 2012-11-06 | Prolor Biotech, Inc. | Long-acting growth hormone and methods of producing same |
| US9458444B2 (en) | 2006-02-03 | 2016-10-04 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8476234B2 (en) * | 2006-02-03 | 2013-07-02 | Prolor Biotech Inc. | Long-acting coagulation factors and methods of producing same |
| US8759292B2 (en) | 2006-02-03 | 2014-06-24 | Prolor Biotech, Llc | Long-acting coagulation factors and methods of producing same |
| US9249407B2 (en) | 2006-02-03 | 2016-02-02 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US8946155B2 (en) | 2006-02-03 | 2015-02-03 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US10221228B2 (en) | 2006-02-03 | 2019-03-05 | Opko Biologics Ltd. | Long-acting polypeptides and methods of producing and administering same |
| US7553941B2 (en) | 2006-02-03 | 2009-06-30 | Modigene Inc | Long-acting polypeptides and methods of producing same |
| WO2007108505A1 (ja) * | 2006-03-22 | 2007-09-27 | Chugai Seiyaku Kabushiki Kaisha | エリスロポエチン溶液製剤 |
| US12203113B2 (en) | 2009-07-09 | 2025-01-21 | Opko Biologics Ltd. | Long-acting coagulation factors and methods of producing same |
| US9663778B2 (en) | 2009-07-09 | 2017-05-30 | OPKO Biologies Ltd. | Long-acting coagulation factors and methods of producing same |
| WO2013157002A1 (en) | 2012-04-19 | 2013-10-24 | Prolor Biotech Inc. | Long-acting oxyntomodulin variants and methods of producing same |
| SG11201503879QA (en) | 2012-11-20 | 2015-06-29 | Opko Biolog Ltd | Method of increasing the hydrodynamic volume of polypeptides by attaching to gonadotrophin carboxy terminal peptides |
| US20150158926A1 (en) | 2013-10-21 | 2015-06-11 | Opko Biologics, Ltd. | Long-acting polypeptides and methods of producing and administering same |
| KR102527180B1 (ko) | 2014-12-10 | 2023-04-27 | 옵코 바이오로직스 리미티드 | 장기간 작용성 ctp-변형된 성장 호르몬 폴리펩타이드의 제조 방법 |
| KR102662956B1 (ko) | 2015-06-19 | 2024-05-03 | 옵코 바이오로직스 리미티드 | 장기-작용성 응고 인자 및 그의 제조 방법 |
| EP4303228B1 (de) | 2016-07-11 | 2026-05-27 | OPKO Biologics Ltd. | Langwirkender gerinnungsfaktor vii und verfahren zur herstellung davon |
Family Cites Families (40)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| IL77081A (en) | 1984-12-04 | 1999-10-28 | Genetics Inst | Dna sequence encoding human erythropoietin process for the preparation thereof and a pharmaceutical composition of human erythropoietin |
| US4745099A (en) | 1985-02-06 | 1988-05-17 | Chugai Seiyaku Kabushiki Kaisha | Pharmaceutical composition for the treatment of the anemia of malignant tumors |
| JP2858752B2 (ja) | 1987-04-10 | 1999-02-17 | オーソ・フアーマシユーチカル・コーポレーシヨン | 正常な哺乳動物のヘマトクリツト値の増大方法 |
| FR2646438B1 (fr) | 1989-03-20 | 2007-11-02 | Pasteur Institut | Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration |
| DE3924705A1 (de) | 1989-07-26 | 1991-01-31 | Boehringer Mannheim Gmbh | Heterobifunktionelle verbindungen |
| SG88714A1 (en) | 1989-11-06 | 2002-05-21 | Cell Genesys Inc | Production of proteins using homologous recombination |
| DE779362T1 (de) | 1989-12-22 | 2001-04-05 | Applied Research Systems Ars Holding N.V., Curacao | DNS-Konstrukten zur Aktivierung und Veränderung der Expression von endogenen Genen |
| US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
| GB9001987D0 (en) | 1990-01-29 | 1990-03-28 | Janssen Pharmaceutica Nv | Improved cyclodextrin based erythropietin formulation |
| US5324650A (en) | 1990-03-20 | 1994-06-28 | E. I. Du Pont De Nemours And Company | Situ process for production of conjugates |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| AU1676992A (en) | 1991-03-18 | 1992-10-21 | Enzon, Inc. | Hydrazine containing conjugates of polypeptides and glycopolypeptides with polymers |
| NZ244778A (en) | 1991-10-21 | 1994-03-25 | Ortho Pharma Corp | Peg imidates and protein derivatives thereof |
| US5968502A (en) | 1991-11-05 | 1999-10-19 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| US5641670A (en) | 1991-11-05 | 1997-06-24 | Transkaryotic Therapies, Inc. | Protein production and protein delivery |
| NZ245015A (en) | 1991-11-05 | 1995-12-21 | Transkaryotic Therapies Inc | Delivery of human growth hormone through the administration of transfected cell lines encoding human growth hormone, which are physically protected from host immune response; the transfected cells and their production |
| ZA933926B (en) | 1992-06-17 | 1994-01-03 | Amgen Inc | Polyoxymethylene-oxyethylene copolymers in conjuction with blomolecules |
| CA2101361A1 (en) | 1992-08-27 | 1994-02-28 | Robert A. Snow | Low diol polyalkylene oxide biologically active proteinaceous substances |
| TW402639B (en) | 1992-12-03 | 2000-08-21 | Transkaryotic Therapies Inc | Protein production and protein delivery |
| NZ250375A (en) | 1992-12-09 | 1995-07-26 | Ortho Pharma Corp | Peg hydrazone and peg oxime linkage forming reagents and protein derivatives |
| US5359030A (en) | 1993-05-10 | 1994-10-25 | Protein Delivery, Inc. | Conjugation-stabilized polypeptide compositions, therapeutic delivery and diagnostic formulations comprising same, and method of making and using the same |
| US5681811A (en) | 1993-05-10 | 1997-10-28 | Protein Delivery, Inc. | Conjugation-stabilized therapeutic agent compositions, delivery and diagnostic formulations comprising same, and method of making and using the same |
| WO1994028024A1 (en) | 1993-06-01 | 1994-12-08 | Enzon, Inc. | Carbohydrate-modified polymer conjugates with erythropoietic activity |
| IL110669A (en) | 1993-08-17 | 2008-11-26 | Kirin Amgen Inc | Erythropoietin analogs |
| US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
| RU2089214C1 (ru) * | 1994-01-06 | 1997-09-10 | Научно-исследовательский центр Санкт-Петербургского медицинского института им.акад.И.П.Павлова | Средство для снижения патологической проницаемости сосудов к белкам |
| US5672662A (en) | 1995-07-07 | 1997-09-30 | Shearwater Polymers, Inc. | Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications |
| DE19535571A1 (de) | 1995-09-14 | 1997-03-20 | Boehringer Mannheim Gmbh | Pharmazeutische Kombinationspräparate und deren Verwendung zur Behandlung von Hämodialysepatienten |
| AU5773798A (en) | 1997-01-29 | 1998-08-18 | Polymasc Pharmaceuticals Plc | Pegylation process |
| WO1998041226A1 (de) | 1997-03-18 | 1998-09-24 | Roche Diagnostics Gmbh | Pharmazeutische kombinationspräparate enthaltend erythropoietin und eisenpräparate |
| EP0885613A1 (de) | 1997-06-21 | 1998-12-23 | Roche Diagnostics GmbH | Verwendung von modifizierten Hämoglobinen zur Behandlung von Anämien und Kombinationspräparate umfassend Erythropoietin und modifiziertes Hämoglobin |
| DE19734293A1 (de) | 1997-08-08 | 1999-02-11 | Boehringer Mannheim Gmbh | Verwendung von pharmazeutischen Kombinationspräparaten enthaltend Erythropoietin und Eisenpräparate zur Behandlung von rheumatischen Erkrankungen |
| WO2000067776A1 (en) * | 1999-05-11 | 2000-11-16 | Ortho-Mcneil Pharmaceuticals, Inc. | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| PE20010288A1 (es) | 1999-07-02 | 2001-03-07 | Hoffmann La Roche | Derivados de eritropoyetina |
| CZ299516B6 (cs) | 1999-07-02 | 2008-08-20 | F. Hoffmann-La Roche Ag | Konjugát erythropoetinového glykoproteinu, zpusobjeho výroby a použití a farmaceutická kompozice sjeho obsahem |
| MEP90708A (hr) | 2000-05-15 | 2011-12-20 | Nova farmaceutska smješa | |
| US20020065214A1 (en) | 2000-11-29 | 2002-05-30 | Adrian Iaina | Method of treating congestive heart failure |
| AU3323002A (en) | 2000-12-20 | 2002-07-01 | Hoffmann La Roche | Erythropoietin conjugates |
| WO2003025583A2 (en) | 2001-09-14 | 2003-03-27 | F. Hoffmann-La Roche Ag | Differential diagnosis of disorders of iron metabolism |
-
2003
- 2003-08-04 US US10/634,477 patent/US7459435B2/en not_active Expired - Lifetime
- 2003-08-20 AU AU2003251713A patent/AU2003251713B2/en not_active Expired
- 2003-08-20 BR BRPI0313792A patent/BRPI0313792B8/pt not_active IP Right Cessation
- 2003-08-20 MX MXPA05002067A patent/MXPA05002067A/es active IP Right Grant
- 2003-08-20 CA CA2496581A patent/CA2496581C/en not_active Expired - Lifetime
- 2003-08-20 WO PCT/EP2003/009194 patent/WO2004019972A1/en not_active Ceased
- 2003-08-20 JP JP2004532098A patent/JP5128048B2/ja not_active Expired - Lifetime
- 2003-08-20 RU RU2005108976/15A patent/RU2305554C2/ru active
- 2003-08-20 AT AT03790911T patent/ATE510556T1/de active
- 2003-08-20 CN CNB038205459A patent/CN1311866C/zh not_active Expired - Lifetime
- 2003-08-20 KR KR1020057003501A patent/KR20050057054A/ko not_active Ceased
- 2003-08-20 ES ES03790911T patent/ES2364651T3/es not_active Expired - Lifetime
- 2003-08-20 PL PL375784A patent/PL209699B1/pl unknown
- 2003-08-20 EP EP03790911A patent/EP1536823B1/de not_active Expired - Lifetime
- 2003-08-27 AR ARP030103092A patent/AR041061A1/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050057054A (ko) | 2005-06-16 |
| ES2364651T3 (es) | 2011-09-08 |
| EP1536823A1 (de) | 2005-06-08 |
| CA2496581A1 (en) | 2004-03-11 |
| WO2004019972A1 (en) | 2004-03-11 |
| AR041061A1 (es) | 2005-04-27 |
| MXPA05002067A (es) | 2005-06-08 |
| AU2003251713A1 (en) | 2004-03-19 |
| EP1536823B1 (de) | 2011-05-25 |
| RU2305554C2 (ru) | 2007-09-10 |
| BRPI0313792B8 (pt) | 2021-05-25 |
| US20040110679A1 (en) | 2004-06-10 |
| AU2003251713B2 (en) | 2006-12-21 |
| BR0313792A (pt) | 2005-07-12 |
| PL209699B1 (pl) | 2011-10-31 |
| US7459435B2 (en) | 2008-12-02 |
| JP2006503821A (ja) | 2006-02-02 |
| RU2005108976A (ru) | 2006-01-27 |
| CA2496581C (en) | 2019-09-03 |
| JP5128048B2 (ja) | 2013-01-23 |
| CN1311866C (zh) | 2007-04-25 |
| BRPI0313792B1 (pt) | 2016-10-18 |
| PL375784A1 (en) | 2005-12-12 |
| CN1678341A (zh) | 2005-10-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE50212455D1 (de) | Verwendung von Dimerdiolen | |
| DE60326874D1 (de) | Neue verwendung von erythropoietin in herzerkrankungen | |
| DE502005006470D1 (de) | Verwendung von sulfonylharnstoffen | |
| DE60312659D1 (de) | Leichtgewicht identifizierung von informationen | |
| DE60311098D1 (de) | Multimodus-spannungsregler | |
| DE60321130D1 (de) | Variation von parametern zur neurostimulation | |
| DE502004011575D1 (de) | Verwendung von Dioldimerfettsäureestern | |
| DE60318920D1 (de) | Induktion von Insulin-produzierende Zellen | |
| FI20021310A7 (fi) | Jauhin | |
| EP1499186A4 (de) | Verwendung von häm-oxygenase-1 und häm-abbauprodukte | |
| DE10295497D2 (de) | Vernetzung von Photoinitiator-initialisierten Polyacrylaten | |
| DE50104706D1 (de) | Verwendung von benzophenanthridinalkaloiden als futterzusatzmittel | |
| DE502005006286D1 (de) | Verwendung von trisubstituierten benzopyranonen | |
| DE50311406D1 (de) | Verwendung von Formkörpern | |
| DE60318819D1 (de) | Hitzestabile mutanten von stärkebiosyntheseenzymen | |
| DE602004026773D1 (de) | Verfahrensherstellung von ethern | |
| DE60327426D1 (de) | Markierung von substraten | |
| DE60315984D1 (de) | Substituierte benzisoxazolsulfonamide mit breitbändiger hiv-protease hemmender wirkung | |
| ATE556564T1 (de) | Zuweisung von zeitschlitzen | |
| ATE474824T1 (de) | Herstellung von olefinen | |
| DE50203046D1 (de) | Verwendung von Esterquats | |
| ATE394140T1 (de) | Verwendung neuer etonogestrelester | |
| DE60314663D1 (de) | Umsetzung von fluorpolymerschmelzen | |
| ATE499348T1 (de) | Stabiler polymorph von bifeprunoxmesilat | |
| ATE348606T1 (de) | Neue verwendung von pipatalin |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1536823 Country of ref document: EP |